中华外科杂志
中華外科雜誌
중화외과잡지
CHINESE JOURNAL OF SURGERY
2011年
9期
820-824
,共5页
周文勇%陈晓峰%张雷%张慧君%王海兵%张辉%赵明川%刘鸿程
週文勇%陳曉峰%張雷%張慧君%王海兵%張輝%趙明川%劉鴻程
주문용%진효봉%장뢰%장혜군%왕해병%장휘%조명천%류홍정
癌,非小细胞,肺%肺切除术%预后
癌,非小細胞,肺%肺切除術%預後
암,비소세포,폐%폐절제술%예후
Carcinoma,non-small-cell lung%Pneumonectomy%Prognosis
目的 研究分析临床分期Ⅰ期接受胸腔镜肺叶切除,术中意外发现微小纵隔淋巴结转移(N2)的非小细胞肺癌患者的近、远期预后.方法 回顾性分析2004年1月至2007年12月术前诊断为早期非小细胞肺癌(cT1-2N0M0,Ⅰ期),而术中或术后意外发现微小纵隔淋巴结转移(pT1-2N2M0,Ⅲa期)患者263例的临床资料.全部患者接受肺叶切除术+系统淋巴结清扫根治性治疗.其中接受胸腔镜肺叶切除术63例(腔镜组),男性37例,女性26例,平均年龄(58±11)岁.同期接受开胸肺叶切除术治疗的为200例(开胸组),男性132例,女性68例,平均年龄(59±11)岁.对比上述两组患者的临床特征及近、远期预后.结果 全部263例患者平均生存时间(34.9±1.2)个月,中位生存时间31个月.腔镜组平均生存时间(40.3±2.2)个月,中位生存时间37个月;开胸组平均生存时间(33.1±1.3)个月,中位生存时间29个月.全部患者1、2、3年生存率为92.0%、57.4%、29.3%,腔镜组1、2、3年生存率为92.1%、82.5%、41.3%,开胸组1、2、3年生存率为92.0%、49.5%、25.5%,两组间差异有统计学意义(x2=5.58,P=0.018).结论 VATS肺叶切除治疗微小N2非小细胞肺癌是安全、有效的.患者经过术前严格的评估,手术中出现意料之外的纵隔淋巴结转移,通过系统的淋巴结清扫后没有必要中转开胸完成手术.
目的 研究分析臨床分期Ⅰ期接受胸腔鏡肺葉切除,術中意外髮現微小縱隔淋巴結轉移(N2)的非小細胞肺癌患者的近、遠期預後.方法 迴顧性分析2004年1月至2007年12月術前診斷為早期非小細胞肺癌(cT1-2N0M0,Ⅰ期),而術中或術後意外髮現微小縱隔淋巴結轉移(pT1-2N2M0,Ⅲa期)患者263例的臨床資料.全部患者接受肺葉切除術+繫統淋巴結清掃根治性治療.其中接受胸腔鏡肺葉切除術63例(腔鏡組),男性37例,女性26例,平均年齡(58±11)歲.同期接受開胸肺葉切除術治療的為200例(開胸組),男性132例,女性68例,平均年齡(59±11)歲.對比上述兩組患者的臨床特徵及近、遠期預後.結果 全部263例患者平均生存時間(34.9±1.2)箇月,中位生存時間31箇月.腔鏡組平均生存時間(40.3±2.2)箇月,中位生存時間37箇月;開胸組平均生存時間(33.1±1.3)箇月,中位生存時間29箇月.全部患者1、2、3年生存率為92.0%、57.4%、29.3%,腔鏡組1、2、3年生存率為92.1%、82.5%、41.3%,開胸組1、2、3年生存率為92.0%、49.5%、25.5%,兩組間差異有統計學意義(x2=5.58,P=0.018).結論 VATS肺葉切除治療微小N2非小細胞肺癌是安全、有效的.患者經過術前嚴格的評估,手術中齣現意料之外的縱隔淋巴結轉移,通過繫統的淋巴結清掃後沒有必要中轉開胸完成手術.
목적 연구분석림상분기Ⅰ기접수흉강경폐협절제,술중의외발현미소종격림파결전이(N2)적비소세포폐암환자적근、원기예후.방법 회고성분석2004년1월지2007년12월술전진단위조기비소세포폐암(cT1-2N0M0,Ⅰ기),이술중혹술후의외발현미소종격림파결전이(pT1-2N2M0,Ⅲa기)환자263례적림상자료.전부환자접수폐협절제술+계통림파결청소근치성치료.기중접수흉강경폐협절제술63례(강경조),남성37례,녀성26례,평균년령(58±11)세.동기접수개흉폐협절제술치료적위200례(개흉조),남성132례,녀성68례,평균년령(59±11)세.대비상술량조환자적림상특정급근、원기예후.결과 전부263례환자평균생존시간(34.9±1.2)개월,중위생존시간31개월.강경조평균생존시간(40.3±2.2)개월,중위생존시간37개월;개흉조평균생존시간(33.1±1.3)개월,중위생존시간29개월.전부환자1、2、3년생존솔위92.0%、57.4%、29.3%,강경조1、2、3년생존솔위92.1%、82.5%、41.3%,개흉조1、2、3년생존솔위92.0%、49.5%、25.5%,량조간차이유통계학의의(x2=5.58,P=0.018).결론 VATS폐협절제치료미소N2비소세포폐암시안전、유효적.환자경과술전엄격적평고,수술중출현의료지외적종격림파결전이,통과계통적림파결청소후몰유필요중전개흉완성수술.
Objective To assess early and late outcomes of patients with minimal mediastinal lymph nodes metastasis N2 non-small cell lung cancer disease unexpectedly detected during the operation, who underwent video-assisted thoracic surgery lobectomy for clinical stage I. Methods This study retrospectively reviewed and analyzed the medical records of 263 patients underwent surgery between January 2004 and December 2007, who were diagnosed as having early-stage non-small cell lung cancer (clinical stage was cT1-2N0M0, stage Ⅰ) before the surgery, but were found to have mini mediastinal lymph nodes metastasis disease (clinical stage was pTI-2N2M0, stage Ⅲa) unexpectedly detected during the operation and after the operation. All patients underwent lobectomy and systematic lymph nodes dissection as radical treatments. Among them, 63 patients underwent video-assisted thoracic surgery (VATS) lobectomy,including 37 male patients (58. 7%) with a mean age of (58 ± 11) years old. Two hundred patients underwent open thoracotomy lobectomy, including 132 male patients (66%) with a mean age of (59 ± 11) years old. To compare and analyze clinical features, early and late outcomes of patients in these two groups.Results A total of 263 patients with an average survival time (34. 9 ± 1.2) months (median 31 months),63 cases in VATS lobectomy group with an average survival time (40. 3± 2. 2) months (median 37 months), 200 cases in open pulmonary lobectomy group with an average survival time (33.1 ±1.3)months (median 29 months). The 1 -, 2-, 3-year over survival rate of all the patients was 92.0%, 57.4%,29. 3%. The 1-, 2-, 3-year survival rate of patients in VATS lobectomy group was 92. 1%, 82. 5%,41.3%. The 1,2,3 year survival rate of patients in thoracotomy lobectomy group was 92. 0%, 49. 5%,25.5%. There was significant difference between the two groups in this factor (x2 =5.58, P =0.018).